Form 8-K - Current report:
SEC Accession No. 0001493152-22-009768
Filing Date
2022-04-13
Accepted
2022-04-13 08:00:18
Documents
14
Period of Report
2022-04-12
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40975
2 ex99-1.htm EX-99.1 31985
3 ex99-1_001.jpg GRAPHIC 11786
  Complete submission text file 0001493152-22-009768.txt   271399

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE mymd-20220412.xsd EX-101.SCH 3021
5 XBRL LABEL FILE mymd-20220412_lab.xml EX-101.LAB 34476
6 XBRL PRESENTATION FILE mymd-20220412_pre.xml EX-101.PRE 22587
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3724
Mailing Address 855 N. WOLFE STREET SUITE 623 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 623 BALTIMORE MD 21205 856-848-8698
MyMD Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

EIN.: 000000000 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36268 | Film No.: 22823676
SIC: 2835 In Vitro & In Vivo Diagnostic Substances